Lung cancers that harbor oncogenic mutations in the KRAS oncogene are refractory to both cytotoxic and targeted chemotherapy. This proposal focuses validating the NF-KB regulator TBK1 and NF-KB signaling as targets in KRAS-dependent lung cancers. These studies will not only provide insight into the biology of the NF-KB in lung cancer but will serve as a foundation for translational studies for the development of novel therapeutic agents.
Showing the most recent 10 out of 80 publications